Positron emission tomography and gallium metabolic imaging in lymphoma.

被引：10

作者：

Coiffier B. ^{[1
]}

机构：

[1] Hospices Civils de Lyon and Université Claude Bernard, CH Lyon-Sud

来源：

Current Oncology Reports | 2001年 / 3卷 / 3期

关键词：

Lymphoma; Positron Emission Tomography; Clin Oncol; Positron Emission Tomography Imaging; Lymphoma Patient;

D O I：

10.1007/s11912-001-0060-1

中图分类号：

学科分类号：

摘要：

Metabolic imaging allows the recognition of active tumor mass because of its fixed tracer. For patients with Hodgkin's disease and non-Hodgkin lymphoma, (67)gallium and (18)fluorodeoxyglucose (FDG) have been employed. This review describes the role of (67)gallium scintigraphy (Ga-scan) and positron emission tomography (PET) in the staging and follow-up of patients with lymphoma. These tools do not appear to be more powerful than conventional imaging for initial staging and treatment choice. Ga-scan is only valid for thoracic examination. PET imaging following treatment resolves the problem of persisting images on CT scan; nearly all patients with FDG uptake have an early relapse. Whether this examination will allow for intensified treatment and possible cure of more patients is yet to be demonstrated.

引用

页码：266 / 270

页数：4

共 82 条

[1] Cheson BD(1993)A predictive model for aggressive non-Hodgkin’s lymphoma N Engl J Med 329 987-994
[2] Horning SJ(1999)Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas J Clin Oncol 17 1244-1253
[3] Coiffier B(1999)Ga-67 scintigraphy in B-cell non-Hodgkin’s lymphoma: correlation of Ga-67 uptake with histology and transferrin receptor expression J Nucl Med 40 40-45
[4] Nejmeddine F(1989)High frequency of benign mediastinal uptake of Gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin’s lymphoma J Clin Oncol 7 1800-1806
[5] Raphael M(1993)The significance of isolated gallium-67 uptake in the hilar lymph nodes of an untreated lymphoma patient Clin Nucl Med 18 1039-1041
[6] Martin A(1978)Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of (F-18)-2-deoxy-2-fluoro-D-glucose J Nucl Med 19 1154-1161
[7] Peylan-Ramu N(1999)Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type Ann Oncol 10 1185-1189
[8] Haddy TB(1997)False-positive FDG-PET imaging of the thymus of a child with Hodgkin’s disease J Nucl Med 38 888-890
[9] Jones E(1999)Normal variants, artifacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine Eur J Nucl Med 26 1363-1378
[10] Larcos G(1997)Lymphoma: role of whole-body 2-deoxy-2F-18 fluoro-D-glucose (FDG) PET in nodal staging Radiology 203 795-800

← 1 2 3 4 5 6 7 8 9 →